Sanofi’s multiple sclerosis pill Aubagio was cleared by the U.K.’s health-cost regulator, less than three months after the overseer said it didn’t have enough information for approval, as the company agreed to a price cut.
The U.K.’s health-cost regulator asked Sanofi for more information on its multiple-sclerosis drug Lemtrada, less than a month after U.S. regulatory advisers said the drug’s trials weren’t adequate to assess its efficacy.
The U.K. Parliament started an inquiry into the safety of blood, tissue and organ screening because of concerns that people without symptoms may harbor the protein thought to cause the human form of mad cow disease.
The U.K. government won’t increase the amount it pays for brand-name medicines in 2014 and 2015 and will raise the total by less than 2 percent a year in the following three years under an agreement with drugmakers.
Computer Sciences Corp., a provider of technology consulting to governments and companies, fell the most in more than five months after signaling that an accounting probe by the Securities and Exchange Commission is escalating.
Britain’s National Health Service will need another overhaul in five years if “damaging” changes being implemented by the government are allowed to continue, the editors of three U.K. health-care publications said.
The U.K.’s National Health Service will have an oversupply of as many as 20,000 doctors by the end of the decade, pressuring medical professionals to accept lower- paid roles or seek work abroad, the Financial Times said.
I’m spending my morning listening to various contractors testify before Congress. Back in the day, when I worked for a tech consultancy, the technical term for what is going on in this hearing was “Not it!”